Short answer

Pfizer is bigger than Johnson & Johnson, holding the top spot in worldwide pharmaceutical sales.

Key points

  • Pfizer leads global pharma sales in 2024.
  • J&J remains a diversified health conglomerate.
  • Pfizer’s strength comes from vaccines and specialty drugs.

Pfizer is larger than Johnson & Johnson, topping the list of pharmaceutical companies by sales.

Pfizer’s sales advantage

In 2024 Pfizer reported the highest revenue among drug makers, driven by its COVID‑19 vaccine portfolio, oncology products and a growing pipeline of rare‑disease therapies. The company’s focus on high‑margin biologics and a strong global distribution network helped it maintain the lead.

Johnson & Johnson’s broader scope

J&J generates revenue from three segments: pharmaceuticals, medical devices and consumer health. While its drug sales lag behind Pfizer’s, the diversified model cushions overall earnings and gives the firm resilience across market cycles.

Both firms are industry titans, but current sales figures place Pfizer ahead of Johnson & Johnson.

Frequently asked questions

How do Pfizer and Johnson & Johnson compare in market capitalization?

Both companies rank among the world’s most valuable health firms, with market caps that often fluctuate around similar levels, but Pfizer’s recent earnings have sometimes given it a slight edge.

Which company has a larger R&D budget?

Pfizer typically spends more on research and development than Johnson & Johnson, reflecting its emphasis on new drug discovery and vaccine production.

Do both companies operate globally?

Yes, both Pfizer and Johnson & Johnson have extensive international operations, selling products in dozens of countries worldwide.

See also

In-depth articles

Related topics